CStone Pharmaceuticals to Raise About HK$1.05 Billion via Discounted Share Placement

CStone Pharmaceuticals ( (HK:2616) ) has issued an update.

CStone Pharmaceuticals has entered into a placing agreement to issue 118 million new shares at HK$8.97 each, a discount of about 6.95% to the last closing price and 7.85% to the five-day average. The new shares will represent roughly 7.40% of the enlarged share capital and will be issued under the company’s general mandate without requiring additional shareholder approval.

The placement is expected to raise approximately HK$1.06 billion in gross proceeds and about HK$1.05 billion net after fees, providing fresh capital to support the company’s operations and growth plans. Completion remains conditional on the Hong Kong Stock Exchange approving the listing of the new shares, and the company has cautioned investors that the placing may or may not proceed depending on satisfaction of these conditions.

More about CStone Pharmaceuticals

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative oncology therapies. Listed in Hong Kong, the company targets cancer treatments for China and global markets, leveraging a pipeline of targeted and immuno-oncology drugs to strengthen its position in the competitive healthcare sector.

Average Trading Volume: 13,527,245

Technical Sentiment Signal: Buy

Current Market Cap: HK$14.64B

See more data about 2616 stock on TipRanks’ Stock Analysis page.